CD 117 Immunoexpression in Invasive Breast Carcinoma: Association with various prognostic parameters
DOI:
https://doi.org/10.21276/apalm.2229Keywords:
Invasive Breast Carcinoma, CD 117, prognostic parametersAbstract
Background: CD 117 (Cluster Differentiation 117), encoded by the proto-oncogene C-Kit is a transmembrane tyrosine kinase growth factor receptor which inhibits apoptosis and potentiates cell proliferation. In normal breast epithelium, c-kit is highly expressed; however, its expression is low or completely lost in primary invasive breast carcinoma, suggesting its role in breast carcinogenesis.
Objective: To evaluate the expression of CD 117 in invasive breast carcinoma and to study its association with various prognostic factors.
Materials and Methods: Fifty cases of invasive breast carcinoma of different histological types and grades were evaluated for CD117 immunoexpression and the association of the same was studied with respect to various prognostic factors, ER/PR receptor status and Her2/neu status.
Results: A statistically significant association was seen between negative expression of CD 117 with increased age (p=0.04), higher tumor grade (p=0.02), positive hormone receptor status (ER; p=0.001, PR; 0.005), negative Her2/neu (p=0.006) and tumors having a microvascular density of more than 19 per high power field (p-0.01).
Conclusion: CD 117 immunoexpression, either negative or positive in invasive breast carcinoma has to be reported on a routine basis as a negative expression projects the prognosis of breast carcinoma patients and a positive expression will identify patients for a potential therapeutic intervention.
References
2. Simon R, Panussis S, Maurer R, Spichtin H, Glatz k, Tapia C, et al. KIT (CD117)-Positive Breast Cancers Are Infrequent and lack KIT Gene Mutations. Clin Can Res. 2004;10(1):178-183.
3. Zhao F, Chen Y, Wu Q, Wang Z, Lu J. Prognostic value of CD 117 in cancer: a meta-analysis. Int J Clin Exp Pathol 2014;7(3):1012-1021.
4. Shams TM, Shams ME. Overexpression of c-kit (CD117) in triple negative breast cancer. Egyptian Journal of Pathology 2011;31:113-117.
5. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tunors. J Clin Oncol 2004;22:4514-4522.
6. Sihto H, Sarlomo, Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, et al. KIT and Platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23:49-57.
7. El-Sayed M and Shafeek MG. Expression of CD 117 in normal and neoplastic breast tissue:the diagnostic significance and correlation with Her-2, estrogen and progesterone receptors in breast cancer. Egyptian Journal of Pathology 2013;33:208-213.
8. Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS, et al. The meaning of the c-kit protooncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis 2003;20:593-7.
9. Tsuura Y, Suzuki T, Honma K, Sano M. Expression of c-KIT protein in proliferative lesions of human breast. Sexual difference and close association with phosphotyrosine status. J Cancer Res Clin Oncol 2002;128:239-46.
10. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M, Chatzipantelis P. Expression of c-kit in common benign and malignant breast lesions. Tumori 2010;96:978-984.
11. Allred DC. ASCO/CAP guidelines recommendation for IHC testing of ER and PR in breast carcinoma. J of clinical oncology. 2010: 28; 2784-2795.
12. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clin Oncol. 2013;31(31):3997–4013.
13. Talaiezadeh A, Jazayeri SN, Nateghi J. Expression of c-kit protein in cancer vs. normal breast tissue. Wspolczesna Onkol 2012;16(4):306-309.
14. Linnekin D. Early signaling pathways activated by c-kit in hematopoietic cells. Int J Biochem Cell Biol 1999;31:1053-74.
15. Tonary AM, Macdonald EZ, Faught W, Senterman MK, Vanderhyden BC. Lack of expression of c-kit in ovarian cancers is assoxiated with poor prognosis. Int J Cancer 2000;89(3):242-50.
16. Tsuura Y, Suzuki T, Honma K and Sano M. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status. J. Cancer Res. Clin. Oncol., 2002;128: 239–246.
17. Chui X, Egami H, Yamashita J, Kurizaki T, Ohmachi H, Yamamoto S, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. British Journal of Cancer 1996;73:1233-1236.
18. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, and Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int. J. Cancer 1992;52: 713–717.
19. Susruthan M, Rajendiran S, Jayanth V, Archana K, Pai V. C-kit expression in breast carcinoma – A study of 62 cases of breast carcinoma. International Journal of Recent Trends in Science and Technology 2015;15(3):597-602.
20. Pillai SKK, Tay A, Nair S, Leong C. Triple Negative breast cancer is associated with EGFR, CK 5/6 and C-KIT expression in Malaysian Women. BMC Clinical Pathology 2012;12:1-18.
21. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346: 645–652.
22. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, and Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg. Pathol. 2001;25:1121–1133.
23. Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol. 2002;20:3568–3569.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Poornima Raikar, B Deepak Kumar, Srinivasa Murthy V
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
